← Back to Clinical Trials
Recruiting NCT07133087

Body Awareness, Upper Extremity Function, and Quality of Life in Breast Cancer Survivors

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Breast Cancer Female
Sponsor Halic University
Study Type OBSERVATIONAL
Phase N/A
Enrollment 42
Sex FEMALE
Min Age 25 Years
Max Age 75 Years
Start Date 2025-05-06
Completion 2025-10-21

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Breast cancer is one of the most common types of cancer among women and one of the leading causes of morbidity and mortality. With increasing survival rates, issues such as treatment-related morbidities and consequently upper extremity dysfunction, reduced body awareness, and decreased quality of life are frequently encountered. In the literature, the impact of treatment-related morbidities-particularly on upper extremity functions, body awareness, and quality of life-among women who have survived breast cancer treatment has not been sufficiently investigated. This gap constitutes a significant shortcoming in terms of clinical practices and the post-treatment period. This study aims to examine the effects of breast cancer treatment on upper extremity functions, body awareness, and quality of life in women who have survived breast cancer treatment, in comparison with a healthy control group. The study will be conducted at Yeditepe University Koşuyolu Hospital between May, 2025, and October, 2025. Participants will include women who have survived breast cancer treatment and a healthy control group matched based on criteria such as age and body mass index. In the study, three separate assessments will be conducted for upper extremity functions: the "Quick Disabilities of the Arm, Shoulder, and Hand" (QuickDASH) questionnaire for upper extremity functionality, a hand dynamometer for grip strength, and the Clinometer device for shoulder joint position sense. The "Body Awareness Questionnaire" will be used to assess body awareness, and the "EORTC QLQ-C30" scale will be used for quality of life assessment. The IBM SPSS Statistics software package will be used for data analysis. In statistical analyses, a significance level of p\<0.05 will be considered.

Eligibility Criteria

Inclusion Criteria for breast cancer survivors: * Being a woman * Being between the ages of 25 and 75 * Having been diagnosed with Stage 0-III breast cancer * Having completed primary treatments (surgery, chemotherapy, and/or radiation therapy) no more than 6 months prior to the assessment date * Having received medical clearance from a physician * Having undergone either breast-conserving surgery or mastectomy due to breast cancer * Willingness to participate in the study voluntarily Exclusion Criteria for breast cancer survivors: * Having a history of rehabilitation due to upper extremity, thoracic, or cervical musculoskeletal disorders within 6 months prior to the breast cancer diagnosis * Having a history of neuromuscular dysfunction * Using medications that may affect neuromuscular performance Inclusion criteria for the control group: * Being a woman * Having a body mass index (BMI) within ±3 kg/m² of the breast cancer survivor group * Being within ±5 years of age compared to the

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}